HBIO

Handel nachbörslich: 5.68

Harvard Bioscience Inc (HBIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Harvard Bioscience Inc Stock (HBIO) Company Profile

Harvard Bioscience Inc

Healthcare (1111)

(508) 893-8999

84 OCTOBER HILL RD, HOLLISTON, MA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HBIO's Discussions on Twitter

Compare HBIO vs ISRG, BDX, ALC, MDLN, RMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HBIO Harvard Bioscience Inc	5.68	25.21M	86.55M	-56.70M	4.87M	-2.5713
ISRG Intuitive Surgical Inc	436.64	155.16B	10.58B	3.00B	2.83B	8.2437
BDX Becton Dickinson Co	147.75	40.68B	21.37B	1.41B	3.07B	3.9437
ALC Alcon Inc	67.70	33.06B	10.63B	819.00M	1.59B	1.6577
MDLN Medline Inc	36.16	31.30B	29.14B	1.07B	1.05B	1.1956
RMD Resmed Inc	207.98	30.18B	5.54B	1.52B	1.74B	10.37

Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-09	Herabstufung	KeyBanc Capital Markets	Overweight → Sector Weight
2023-03-10	Hochstufung	The Benchmark Company	Speculative Buy → Buy
2021-01-07	Hochstufung	The Benchmark Company	Speculative Buy → Buy
2020-12-09	Eingeleitet	Northland Capital	Outperform
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Overweight
2019-07-08	Herabstufung	Janney	Buy → Neutral
2018-01-24	Bestätigt	Janney	Buy
2018-01-23	Bestätigt	The Benchmark Company	Buy
2016-11-17	Eingeleitet	Singular Research	Buy
2015-07-28	Eingeleitet	The Benchmark Company	Buy

Alle ansehen

Harvard Bioscience Inc Aktie (HBIO) Neueste Nachrichten

Finanzdaten der Harvard Bioscience Inc-Aktie (HBIO)

Harvard Bioscience Inc-Aktie (HBIO) Insiderhandel

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
DENELSKY STEPHEN J	Director	Mar 17 '26	Buy	4.87	10,000	48,700	21,000
Snider William	Director	Mar 16 '26	Buy	4.99	12,525	62,500	23,525
Snider William	Director	Mar 17 '26	Buy	4.85	8,475	41,104	32,000
Duke John D	Chief Executive Officer	Mar 16 '26	Buy	5.01	5,000	25,050	105,000

Harvard Bioscience Inc (HBIO)

Harvard Bioscience Inc Stock (HBIO) Company Profile

Compare HBIO vs ISRG, BDX, ALC, MDLN, RMD

Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades

Harvard Bioscience Inc Aktie (HBIO) Neueste Nachrichten

Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli

HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI

Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser

Harvard Bioscience (HBIO) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.33Real Trader Insights - Newser

Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS

HBIO Stock Price, Quote & Chart | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill

Harvard Bioscience, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-05-15 - Seeking Alpha

Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts - Investing.com UK

Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts By Investing.com - Investing.com Australia

Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake - Stock Titan

Harvard Bioscience Transitions to Translational Science Focus in 2026 - HarianBasis.co

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript - Insider Monkey

Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations - GuruFocus

Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss By Investing.com - Investing.com Nigeria

Harvard Bioscience Q1 2026 Earnings Call Transcript - MarketBeat

HBIO Maintains Positive Outlook for FY26 Financial Performance - GuruFocus

Harvard Bioscience (HBIO) Reports Q1 Earnings and Reaffirms 2026 Revenue Guidance - GuruFocus

Discontinued operations of Harvard Bioscience, Inc. – FWB:HBI0 - TradingView

Harvard Bioscience Reaffirms Full-Year 2026 Financial Guidance >HBIO - Moomoo

Harvard Bioscience: Consolidation of Manufacturing Operations Progressing on Schedule >HBIO - Moomoo

Harvard Bioscience (NASDAQ: HBIO) posts Q1 2026 loss as debt costs rise - Stock Titan

Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

HBIO Forecasts Q2 Margins and Revenue Growth - GuruFocus

HBIO Sees Q1 Revenue at $20.8M, Positive Trends in Product Adoption - GuruFocus

Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com UK

Harvard Bioscience reaffirms 2026 outlook for 2%-4% revenue growth as Project Viking targets $4M annual savings - MSN

Harvard Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Harvard Bioscience (HBIO) Q1: EPS Not Disclosed, Revenue $20.8M - GuruFocus

Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss - Investing.com

Harvard Bioscience Still Sees 2026 Revenue Up 2%-4% >HBIO - Moomoo

Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops By Investing.com - Investing.com South Africa

Harvard Bioscience Announces Q1 2026 Financial Results: $20.8M Revenue, 59% Gross Margin, Key SEC Filing Details 9 - Minichart

Harvard Bioscience Accelerates Growth with Human-Relevant Translational Tools, Leading Recurring Revenue and Innovation in Preclinical Research (May 2026) 10121415 - Minichart

Harvard Bioscience Still Sees 2026 Adjusted Ebitda Up 6%-10% >HBIO - Moomoo

Harvard Bioscience Inc (NASDAQ:HBIO) Q1 Results Show Revenue Miss Offsets Earnings Beat - ChartMill

HARVARD BIOSCIENCE ($HBIO) Releases Q1 2026 Earnings - Quiver Quantitative

Harvard Bioscience Announces First Quarter 2026 Financial Results - The Manila Times

Harvard Bioscience: Q1 Earnings Snapshot - marketscreener.com

Harvard Bioscience (NASDAQ: HBIO) details debt refinancing, FY26 outlook and $7M convertible loan - Stock Titan

Harvard Bioscience (NASDAQ: HBIO) Q1 2026 margin up as loss shrinks - Stock Titan

Inventory turnover of Harvard Bioscience, Inc. – LS:A423J5 - TradingView

MSN Money - MSN

Harvard Bioscience Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView

Harvard Bioscience to Participate in Upcoming Investor Conferences - 富途牛牛

HBIO News | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill

Finanzdaten der Harvard Bioscience Inc-Aktie (HBIO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Harvard Bioscience Inc-Aktie (HBIO) Insiderhandel

Ähnlich wie HBIO